spacer
home > white papers > Characterisation of Biopharmaceutical Proteins - Reading Scientific Services Ltd (RSSL)
WHITE PAPERS
logo_Reading_Scl.php

Reading Scientific Services Ltd (RSSL)

phone +44 (0)118 918 4076
email enquiries@rssl.com
web http://www.rssl.com/services/pharmaceuticalandhealthcare
email RSSL, Reading Science Centre, Whiteknights Campus, Pepper Lane, Reading, Berkshire RG6 6LA, UK

Characterisation of Biopharmaceutical Proteins

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein´┐Żs primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.

Characterisation of Biopharmaceutical Proteins
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Turkish Cargo maintains its steady growth.

According to the data obtained by WACD, the international air cargo information provider, in May; Turkish Cargo, the global air cargo brand providing service to 124 countries around the world, increased its tonnage rate by 7.1 percent, and grew substantially across the industry which shrank by 5.1 percent in the global air cargo market.
More info >>


White Papers

The Impact of Components on Drug Quality and Risk Mitigation

West Pharmaceutical Services, Inc.

Expectations for quality by regulatory agencies are increasing at a very fast pace, especially for prefilled drug delivery formats, thanks to increased focus on reducing risk to patient safety. The trend has resulted in delays for new drug applications, more recalls of marketed products and even drug shortages if the container system and drug contents are suspect for quality issues. The pharmaceutical market is now requiring manufacturers of containers and components to meet new expectations with a quality culture and very high product reliability. The need to bridge the gap and provide superior quality products has been a driver for manufacturing technology investments, more robust control strategies and the introduction of next generation elastomer components.
More info >>


Industry Events

Outsourcing in Clinical Trials West Coast

3-4 March 2020, Hyatt Regency San Francisco Airport

Last year's event was attended by 700+ clinical trial stakeholders. Following its success, we are pleased to forecast the 2020 edition will be even in larger scale, with a great speaker line up and engaging content. This edition aims to give attendees practical take-aways which they can apply to their studies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement